-
公开(公告)号:US20050276785A1
公开(公告)日:2005-12-15
申请号:US11147492
申请日:2005-06-07
申请人: Georg Groetzbach , Joachim-Friedrich Kapp , Uwe Kuehl , Heinz-Peter Schultheiss , Olaf Sowade , Claus-Steffen Stuerzebecher
发明人: Georg Groetzbach , Joachim-Friedrich Kapp , Uwe Kuehl , Heinz-Peter Schultheiss , Olaf Sowade , Claus-Steffen Stuerzebecher
CPC分类号: A61K38/215
摘要: The present invention relates to pharmaceutical compositions comprising a therapeutically effective dose of an isolated interferon (IFN) or IFN mutein for treatment of cardiomyopathy and of endothelial dysfunction, and to methods of treating cardiomyopathy and methods of treating endothelial dysfunction using such pharmaceutical compositions. Particularly, the pharmaceutical compositions of the present invention comprise a therapeutically effective dose of an isolated, human IFN, or IFN mutein that is a variant of an isolated human IFN, e.g., an isolated, native, human IFNβ or an isolated, native, human IFNα.
摘要翻译: 本发明涉及包含治疗有效剂量的用于治疗心肌病和内皮功能障碍的分离的干扰素(IFN)或IFN突变蛋白的药物组合物,以及使用这种药物组合物治疗心肌病的方法和治疗内皮功能障碍的方法。 特别地,本发明的药物组合物包含治疗有效剂量的分离的人IFN或IFN突变蛋白,其是分离的人IFN的变体,例如分离的天然人IFNBeta或分离的天然人 IFNalpha。